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A B S T R A C T
Background
Subarachnoid haemorrhage may result in seizures both acutely and in the longer term. The use of antiepileptic drugs (AEDs) in the
primary and secondary prevention of seizures after subarachnoid haemorrhage is uncertain, and there is currently no consensus on
treatment.
Objectives
To assess the effects of AEDs for the primary and secondary prevention of seizures after subarachnoid haemorrhage.
Search methods
We searched theCochrane EpilepsyGroup Specialised Register, theCochrane Central Register of Controlled Trials (CENTRAL) (2013,
Issue 1) in The Cochrane Library, and MEDLINE (1946 to 12th March 2013). We checked the reference lists of articles retrieved from
these searches.
Selection criteria
We considered all randomised and quasi-randomised controlled trials in which patients were assigned to a treatment (one or more
AEDs) or placebo.
Data collection and analysis
Two review authors (RM and JK) independently screened and assessed the methodological quality of the studies. If studies were
included, one author extracted the data and the other checked it.
Main results
No relevant studies were found.
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Authors’ conclusions
There was no evidence to support or refute the use of antiepileptic drugs for the primary or secondary prevention of seizures related to
subarachnoid haemorrhage. Well-designed randomised controlled trials are urgently needed to guide clinical practice.
P L A I N L A N G U A G E S U M M A R Y
Antiepileptic drugs for the primary and secondary prevention of seizures after subarachnoid haemorrhage
The purpose of this review was to examine whether the routine use of antiepileptic medication in preventing epileptic seizures following
subarachnoid haemorrhage can be justified. This includes patients who have not yet had a seizure (primary prevention) and those who
have already had one (secondary prevention).
Epileptic seizures are caused by abnormal, rhythmic discharges of nerve cells within the brain leading to involuntary changes in body
movement or function, sensation, awareness, or behaviour. Following a subarachnoid haemorrhage seizures can occur in up to 25% of
patients, triggered by nerve cell damage caused by the blood itself, the formation of scar tissue, and swelling around the site of bleeding.
Recurrent uncontrolled seizures can cause considerable morbidity and mortality, preventing neurological recovery and reducing quality
of life. Conversely, side effects of antiepileptic medication include diarrhoea, nausea and vomiting, drowsiness, dizziness, agitation,
tremor, confusion and skin rash. These need to be considered when prescribing antiepileptic medication, as the medication itself may
hinder neurological recovery and rehabilitation.
To date there have been no randomised controlled trials comparing antiepileptic drugs with placebo following subarachnoid haem-
orrhage. Some retrospective studies have suggested worse outcomes in patients on higher doses and a longer duration of antiepileptic
treatment, as explained in the review, but they do not provide the strength of evidence required for their use as a routine recommen-
dation.
Currently, there is insufficient evidence to justify the routine use of antiepileptic medication for the primary and secondary prevention
of seizures after subarachnoid haemorrhage, and a double blind randomised controlled trial comparing antiepileptic medication with
placebo would help to clarify this important question.
B A C K G R O U N D
Description of the condition
Subarachnoid haemorrhage (SAH) occurs when blood is released
into the subarachnoid space that surrounds the brain and spinal
cord (Van Gijn 2001). Although SAH accounts for only 3% of all
strokes, it is associated with 5% of all stroke deaths, and for more
than 25% of potential life years lost through stroke (Van Gijn
2001). Significant developments have taken place in the manage-
ment of SAH in the past three decades, including the use of early
angiography, endovascular coil embolisation and more sophisti-
cated intensive care support (Butzkueven 2000). Consequently,
the outcome of patients with SAH has improved substantially. In
the 1970s, the early mortality rate after SAH was as high as 65%
(Fogelholm 1981), but in recent years it has fallen to between 20%
and 30% (Qureshi 2005). However, 50% of long-term survivors
are still permanently disabled (Claassen 2003).
Seizures and epilepsy are well recognised complications after SAH.
Seizures can occur at different time points after SAH:
a. ’onset’ seizures occur around the time of the initial haemorrhage;
b. ’early’ seizures occur during the first two weeks of recovery after
SAH or surgery;
c. ’late’ seizures occur after the first two weeks of recovery post-
SAH or following surgery (Bederson 1997; Buczacki 2004).
However, the definitions of early and late seizures differ between
authors, and there is conflicting evidence onwhether onset seizures
predict late seizures or post-SAH epilepsy (Butzkueven 2000;
Byrne 2003). Post-SAH epilepsy refers to the condition where at
least two spontaneous seizures occur (some have specified that they
should be separated by at least 24 hours) after the first fewmonths
following the initial SAHor operation (Buczacki 2004; Lin 2003).
One study found that post-SAH epilepsy was more frequent in
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patients with severe residual neurological impairment (the risk of
developing epilepsy was 28% at one year and 47% at four years)
compared with patients who had mild or no impairment (the risk
was 12% at one year and 15% at four years) (Olafsson 2000).
The majority of post-SAH seizure types are secondary generalised
tonic-clonic seizures or simple partial seizures (Claassen 2003;
Lin 2003). Pinto 1996 reported that although early post-SAH
seizures did not predict longer-term prognosis, they were related
to a higher risk of re-bleeding, death or dependency by the time
of hospital discharge. However, other studies have not found such
an association (Sundaram 1986).
The incidence of post-SAH seizures varies widely between obser-
vational studiesmainly as a result of differences in the patient selec-
tion methods, the definitions used to describe the timing of post-
SAH seizures, and the administration of prophylactic antiepileptic
drugs (AEDs) after admission. In a previous literature review (Lin
2003), 4% to 26% of patients with SAHhad onset seizures, 1% to
28% had early seizures (within the first twoweeks) and 1% to 35%
had late seizures (after two weeks) (Byrne 2003; Lin 2003). Mod-
ern techniques, such as continuous electroencephalogram (EEG)
monitoring, have assisted with the less common diagnosis of non-
convulsive seizures and non-convulsive status epilepticus (Vespa
2005). In one study, 18% of the patients admitted to neurolog-
ical intensive care units with SAH had non-convulsive seizures
(Claassen 2004). Another study reported that 3% of such patients
were in non-convulsive status epilepticus (Dennis 2002), and this
should be considered in patients with poor neurological status or
deterioration (Lanzino 2011).
Risk factors associated with the occurrence of post-SAH seizures
include increasing age, a history of hypertension, poor neurological
grade (for example Hunt and Hess grade > 3), the presence of an
anterior circulation aneurysm (especially middle cerebral artery
aneurysms), the volume of subarachnoid blood and occurrence of
aneurysmal re-bleeding, vasospasm, cerebral infarction, subdural
haematoma, hyponatraemia and hydrocephalus (Claassen 2003;
Lin 2003; Ohman 1990). Intracranial aneurysm treatment, either
by neurosurgical clipping or endovascular coiling, has a seizure
rate of about 2% (Lanzino 2011). Unruptured aneurysms treated
with surgical clipping have reported seizure rates of 9.2% to 13%,
whereas with coiling this ranges between 6.2% and 8.3% (Hart
2011; Hoh 2011). Endovascular intervention had lower seizure
rates (1.3% to 3.3%) compared with surgery (2.2% to 5.2%) in
the first year (Hart 2011; Molyneux 2005).
Description of the intervention
There is substantial variability among physicians in the use of
AEDs for patients after SAH (Rhoney 2000). Some physicians
recommend using prophylactic AEDs for all patients with SAH,
especially those undergoing open aneurysmal surgery (King 1994;
Ohkuma 1990; Olafsson 2000). Others recommend using AEDs
for the in-hospital stay, but not beyond discharge (Varelas 2004).
A third approach recommends targeting AEDs to patients with
risk factors that predict future seizure (Butzkueven 2000). Some
clinicians do not recommend the routine use of AEDs following
SAH (Buczacki 2004; Byrne 2003; Claassen 2003), suggesting
that further randomised controlled trials are required (Lin 2003;
Rapaport 2012; Rhoney 2000). This lack of consensus stems from
uncertainty regarding the need for AEDs, the best AED to use,
which patients should receive prophylactic AEDs, and the optimal
dosage and duration of treatment (Rapaport 2012; Rhoney 2000;
Riordan 2010).
How the intervention might work
The intervention might work if, in offering routine prophylaxis
to patients with SAH, the risk of seizures exceeded the risk of
AED-related adverse effects.Why is seizure prevention important?
There is conflicting evidence about whether or not in-hospital
post-SAH seizures are associated with a poor functional outcome.
Some studies have suggested seizures correlate with poorer out-
comes (Butzkueven 2000; Claassen 2003). In 247 patients admit-
ted to a neurological intensive care unit with SAH, the occur-
rence of in-hospital seizures was an independent predictor of one-
year mortality (65% with seizures versus 23% without seizures)
(Claassen 2003). This may reflect the severity of the SAH itself, as
one retrospective study showed that the higher the grade of SAH,
the greater the likelihood of seizure, but there was little association
with a poorer prognosis at one year (Lin 2008). Why are AED-
related adverse effects significant? Some authors have suggested
that poor patient recovery might actually be caused by AED treat-
ment itself, particularly with phenytoin, rather than seizure ac-
tivity (Claassen 2003; Naidech 2005; Rosengart 2007). A num-
ber of studies have assessed neurological outcomes following short
and long-term phenytoin treatment (Chumnanvej 2007; Naidech
2005). Poorer outcomes were associated with higher doses and
longer duration of phenytoin treatment. In comparing levetirac-
etam with phenytoin, levetiracetam use resulted in a higher short-
term seizure recurrence (Murphy-Human 2011), but better long-
termneurological outcomes and fewer adverse effects (Lewis 2009;
Szaflarski 2010). There is also evidence from animal and human
studies that the administration of certain AEDs after brain injury
(including stroke and SAH) might lower the chance of a good
functional recovery (Brailowsky 1986; Claassen 2003; Naidech
2005).
Why it is important to do this review
It is important to do this review to establish whether the use
of AEDs in seizure prevention post-SAH can be justified, given
the morbidity and mortality associated with untreated epileptic
seizures and the potential adverse effects of AED treatment.
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O B J E C T I V E S
The main aim was to assess the effects of AEDs for the primary
and secondary prevention of seizures after SAH. For primary pre-
vention, we examined whether AEDs reduced the likelihood of
seizures in patients who had had an SAH, but not had a seizure.
For secondary prevention, we examined whether AEDs reduced
the likelihood of further seizures in patients who had had an SAH
and at least one post-SAH seizure.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered all randomised and quasi-randomised controlled
trials in which patients were assigned to a treatment group (that
is receiving at least one AED) or a control group (that is receiving
placebo or no treatment).
Types of participants
For a detailed description of the internationally accepted defini-
tions for seizures and epilepsy, please refer to Fisher 2005; for the
different types of epileptic seizures, please refer to Engel 2001 and
Engel 2006 (by the International League Against Epilepsy). In this
review, we considered all studies that recruited patients with a di-
agnosis of SAH, regardless of whether they had or had not had
post-SAH seizures. The diagnosis of SAH was confirmed by neu-
roimaging using computed tomography (CT) or magnetic reso-
nance (MR) imaging, with or without lumbar puncture (Van Gijn
2001). Studies that exclusively recruited patients with cerebral in-
farction, primary intracranial haemorrhage, intracranial venous
thrombosis or non-stroke conditions (including subdural haem-
orrhage, extradural haemorrhage, infection- or tumour-related in-
farction or haemorrhage) were excluded. Patients with a history of
epilepsy were excluded. In cases where studies recruited a mixture
of patients with and without a history of epilepsy, attempts were
made to extract only the results related to those patients without
a history of epilepsy.
Children or adults with clinically overt generalised or focal seizures
were included, regardless of whether EEGmonitoring was used to
confirm the diagnosis. For studies that included patients with non-
convulsive seizures diagnosed only by EEG (Bearden 2008), the
results for these patients were extracted and analysed separately. In
cases where studies recruited patients who had prior neurosurgi-
cal procedures (for example aneurysmal clipping or coil emboli-
sation) for SAH, the results for these patients were extracted and
analysed separately from those of patients who had not received
neurosurgery.
Types of interventions
The AEDs included were: carbamazepine, clobazam, clonazepam,
diazepam, ethosuximide, gabapentin, lamotrigine, levetiracetam,
lorazepam, oxcarbazepine, phenytoin, phenobarbitone, primi-
done, sodiumvalproate, tiagabine, topiramate, vigabatrin and zon-
isamide. We considered all trials in which the intervention was
compared with a placebo or no treatment. Studies comparing dif-
ferent AEDs were excluded.
Types of outcome measures
Primary outcomes
1. Proportion of patients who experienced clinical seizures in
the scheduled follow-up period. In cases where seizures occurred,
we noted their nature (generalised or focal), timing and whether
an EEG was performed to aid the diagnosis and seizure
classification.
2. Proportion of patients with a previous seizure who achieved
remission for a predefined period of time (e.g. 12 or 24 months).
3. Proportion of patients who withdrew from the allocated
treatment within the scheduled follow-up period. This was a
composite outcome that took into account several factors,
including adverse events, compliance and effectiveness of
treatment. We were particularly interested in the occurrence of
side effects for the different AEDs, which might be physical or
neurobehavioural (e.g. problems with memory, attention and
performance skills).
4. Proportion of patients who had either died or were
dependent at the end of the scheduled follow-up period.
’Independent’ individuals were defined as those who did not
require regular physical assistance from another person for
activities of daily living such as mobility, dressing, transfers and
feeding. ’Dependent’ individuals were those who failed to meet
one or more of these criteria.
Other outcomes of interest
1. Quality of life (e.g. using a recognised scoring system such
as the Short Form-36 (SF-36) or EuroQol).
2. Duration of stay for the acute phase of stroke recovery.
3. ’Optimal’ duration of treatment (i.e. the length of time that
the intervention should be administered).
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Search methods for identification of studies
This review drew on the search strategies developed for the
Cochrane Epilepsy Group and identified relevant studies in the
Cochrane Epilepsy Group Specialized Register.
We searched the following databases:
1. Cochrane Epilepsy Group Specialized Register (15 March
2013) using the search strategy outlined in Appendix 1;
2. the Cochrane Central Register of Controlled Trials
(CENTRAL) (2013, Issue 1) in The Cochrane Library using the
search strategy outlined in Appendix 2; and
3. MEDLINE (Ovid) (1946 to 12 March 2013) using the
search strategy outlined in Appendix 3.
We also checked the reference lists of articles retrieved from the
above searches.
Data collection and analysis
Selection of studies
One review author (RM) screened the titles, abstracts and key-
words of publications identified by the searches to assess their eli-
gibility. Publications that did not meet the inclusion criteria were
excluded at this stage. A paper copy of the full publication of each
study that was relevant was obtained. Two review authors (RM
and JK) assessed these studies according to pre-specified selection
criteria.
Data extraction and management
One review author (RM) recorded the data on an extraction form.
Another review author (JK) independently checked the extracted
data.Data reported by the published sources were used for analyses
in this review. We extracted demographic data (for example total
number of participants randomly assigned, number of participants
per group, and age and sex of participants) and possible confound-
ing factors (for example timing of randomisation, method of SAH
diagnosis, level of sedation after surgery, location of aneurysm,
severity of neurological deficit, presence of vasospasmor secondary
cerebral infarction, history of epilepsy, other comorbid disorders,
number of patients who were lost to follow-up, duration of follow-
up, and method of treatment, such as aneurysmal clipping or coil
embolisation).
Assessment of risk of bias in included studies
Two review authors (RM and JK) independently assessed the
methodological quality of all the included studies and recorded
the findings. We noted the important aspects of methodology:
study design, type of control, method of allocation concealment,
completeness of follow-up, and the presence of blinding for as-
sessments of non-fatal outcomes.
Data synthesis
Data analysis was designed according to the guidelines set out by
The Cochrane Collaboration regarding statistical methods. Pri-
mary analyses were by intention to treat. For dichotomous data,
we expressed the relative treatment effects as an odds ratio with
95% confidence interval. For continuous data, we calculated the
weightedmean difference with 95% confidence interval. A P value
of less than 0.05 was considered statistically significant. Clinical
heterogeneity was assessed by the distribution of demographic and
prognostic variables across the treatment and control groups. Sta-
tistical heterogeneity among the studies was tested using the I2
statistic. In cases where the results could be sensibly combined
and there was no significant clinical or statistical heterogeneity, a
meta-analysis was undertaken using a fixed-effect or random-ef-
fects model, or both. Sensitivity analyses were undertaken to test
the robustness of the meta-analysis as described above. The influ-
ence of the following factors on the overall results was assessed:
methodological quality, excluding the study with the smallest or
largest sample size, and removing the study with the smallest or
largest treatment effects.
R E S U L T S
Description of studies
Results of the search
A total of 194 studies were identified by the search: 50 records
were screened, 42 were initially excluded, and the remaining eight
were excluded with reasons following analysis of the full texts. The
eight studies were excluded due to lack of randomisation of the
AED versus placebo, and most of these studies were retrospective
analyses. Consequently, no studies met the inclusion criteria, see
Figure 1.
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Figure 1. Study flow diagram.
Excluded studies
No studies provided a randomised controlled trial of an AED
versus placebo, but there were a number of retrospective analyses
which provideduseful informationuponwhich future randomised
studies could be based. See Characteristics of excluded studies.
Risk of bias in included studies
No studies were included in the review.
Effects of interventions
No studies met the inclusion criteria.
D I S C U S S I O N
The purpose of this review was to assess the effects of AEDs for the
primary and secondary prevention of seizures after SAH. None
of the studies selected in the review could be used for further
analysis as there were no randomised or quasi-randomised con-
trolled trials comparing antiepileptic drugs (AEDs) with placebo
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or no drug. As demonstrated by the table of excluded studies,
the data that are currently available were mainly limited to ret-
rospective analyses following a change in AED protocol, rather
than randomised, placebo controlled trials (Chumnanvej 2007;
Murphy-Human 2011; Naidech 2005; Szaflarski 2010). These
have limited applicability both due to their retrospective nature
and the small number of patients studied.
International guidelines suggest that prophylactic AEDs should
not be routinely prescribed, but considered in selected cases.
The American Stroke Association (Bederson 2009) states that for
aneurysmal SAH, AEDprophylaxismay be considered in the post-
haemorrhagic period and longer term for those with risk factors
for seizure recurrence. This includes prior seizure, parenchymal
infarct or haematoma and a middle cerebral artery aneurysm. Eu-
ropean Stroke Initiative (ESI) Guidance on intracerebral haemor-
rhage (Steiner 2006) recommends consideration of prophylactic
AEDs for seven days in patients with lobar haemorrhage, after
which AED treatment should be stopped. Should seizures recur,
the ESI recommends AEDs be restarted and continued for 30 days
then stopped following a gradual reduction in dose.
Given the lack of robust evidence to determine best practice, we
recommend that a large randomised, double blind, placebo con-
trolled trial is conducted to assess the effectiveness, adverse event
profile and optimum duration of AEDs to prevent seizures follow-
ing SAH. Examples would be double blind randomised trials com-
paring phenytoin with placebo and levetiracetam with placebo.
The results of such studies will then inform decision making in
weighing up the benefits of AEDs in both primary and secondary
seizure prophylaxis against the risk of long-term adverse neurolog-
ical, cognitive and functional outcomes.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Currently, there is insufficient evidence to support the routine use
of antiepileptic drugs for the primary or secondary prevention of
seizures after subarachnoid haemorrhage.
Implications for research
More research is needed to assess the efficacy and tolerability of
antiepileptic drugs for the primary and secondary prevention of
seizures after subarachnoid haemorrhage. Future studies should
be randomised double-blind trials comparing one or more AEDs
to placebo. These should aim to recruit large numbers of patients
and generate answers to the optimal dosing, timing and duration
of AED treatment as well as defining side effects and longer-term
cognitive and functional outcomes.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Chumnanvej 2007 Not a randomised controlled trial. Patients allocated to short (3 days) or longer-term (until hospital dis-
charge) phenytoin treatment with no comparison with placebo
Lewis 2009 Retrospective analysis examining levetiracetam and phenytoin in seizure prophylaxis
Murphy-Human 2011 Not a randomised controlled study, retrospective analysis of seizure recurrence based on extended phenytoin
use versus 3 days of levetiracetam
Naidech 2005 Not a randomised controlled trial. Calculation of phenytoin “burden” based on average serum levels and
functional and cognitive outcomes then assessed
Rapaport 2012 Retrospective analysis of the outcome of antiepileptics used in non-traumatic intracranial haemorrhage, not
a randomised controlled trial
Rhoney 2000 Retrospective analysis of patient charts, not a randomised controlled trial
Rosengart 2007 Retrospective analysis of AED prescribing patterns in patients randomised to tirilizad assessing neurological
outcome and in-hospital complications. Not a randomised controlled trial of AED medication
Szaflarski 2010 Randomised single blind trial, but compared levetiracetam with phenytoin rather than placebo; 89% of
patients with traumatic brain injury rather than subarachnoid haemorrhage
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